Experimental cocktail aims to outsmart Drug-Resistant melanoma

NCT ID NCT04903119

Recruiting now Disease control Sponsor: Rina Plattner Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether adding nilotinib to standard BRAF/MEK inhibitor therapy can help people with advanced melanoma whose cancer has stopped responding to treatment. About 30 participants will receive the drug combination to see if it is safe and tolerable. The goal is to find the best dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nilotinib combined with dabrafenib and trametinib or encorafenib and binimetinib
What this could lead to: If it works, this could offer a new treatment option for people with advanced melanoma whose current therapy has stopped working.
What could go wrong: This is a very early, small phase 1 trial focused on safety and dosing, not on effectiveness. The combination may cause significant side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAF GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAF GENE MUTATION METASTATIC MELANOMA

Contacts and locations

Locations

Markey Cancer Center
RECRUITING

Lexington, Kentucky, 40536, United States
St. Luke's University Health Network
RECRUITING

Easton, Pennsylvania, 18045, United States
University of Iowa
NOT_YET_RECRUITING

Iowa City, Iowa, 52242, United States
Vanderbilt-Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.